Flavedon 20mg Tablet(Trimetazidine 20mg)

Description

Flavedon 20mg Tablet (Trimetazidine 20mg) — Complete Clinical and Patient Information Guide

Product Overview

Flavedon 20mg Tablet (Trimetazidine 20mg) contains Trimetazidine Dihydrochloride 20mg as its active pharmaceutical ingredient, belonging to the metabolic anti-ischaemic agent (3-ketoacyl CoA thiolase inhibitor) — adjunct anti-anginal. It is clinically indicated for stable angina pectoris (adjunct therapy when symptoms are not adequately controlled by first-line haemodynamic anti-anginal agents — beta-blockers, calcium channel blockers, nitrates) — EMA-restricted indication. This guide has been prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established cardiovascular clinical guidelines.

Flavedon 20mg provides trimetazidine 20mg — the prototypical myocardial metabolic agent offering a mechanistically distinct approach to stable angina management through cellular energy efficiency optimisation, providing complementary benefit when combined with haemodynamic anti-anginal medications.

About Flavedon 20mg and Its Active Ingredient

Trimetazidine Dihydrochloride 20mg is the pharmacologically active compound in Flavedon 20mg. Cardiovascular medications are among the most safety-critical drugs prescribed — interactions with other heart medications, anticoagulants, and antihypertensives can have life-threatening consequences, and abrupt discontinuation of certain cardiac drugs (beta-blockers, anticoagulants) without medical guidance can precipitate dangerous rebound phenomena. All cardiovascular pharmacotherapy decisions require specialist or physician oversight, with regular monitoring and dose optimisation based on clinical response, ECG findings, blood pressure recordings, and relevant biochemical parameters.

Mechanism of Action

Trimetazidine (1-(2,3,4-trimethoxybenzyl)piperazine) is a metabolic anti-ischaemic agent — the first pharmacologically validated representative of this mechanistic class. Unlike haemodynamic anti-anginal drugs (nitrates, beta-blockers, calcium channel blockers) that reduce anginal symptoms by altering cardiac blood supply or demand, trimetazidine acts at the cellular metabolic level within ischaemic cardiomyocytes. Its primary mechanism is selective inhibition of mitochondrial long-chain 3-ketoacyl CoA thiolase (3-KAT) — the final enzyme in mitochondrial beta-oxidation of long-chain fatty acids. During cardiac ischaemia, myocardial cells shift from their normal aerobic metabolism (using both fatty acids and glucose) toward predominant fatty acid oxidation, which is energetically inefficient under hypoxic conditions — generating significant ROS, accumulating toxic acylcarnitines, and causing intracellular acidosis. By inhibiting 3-KAT, trimetazidine reduces fatty acid oxidation and simultaneously promotes glucose oxidation (more oxygen-efficient, generating more ATP per mole of oxygen consumed and less lactate under ischaemic conditions). This metabolic shift — from fatty acid to glucose oxidation — improves the oxygen efficiency of ATP production in ischaemic myocardium without affecting haemodynamics, heart rate, or blood pressure. Trimetazidine additionally maintains intracellular pH, reduces calcium overload, decreases ROS generation, and has anti-inflammatory properties in ischaemic myocardium.

A clear understanding of the pharmacological mechanism helps explain the clinical requirements: why timing, dose titration, monitoring, drug interactions, and contraindications exist. Healthcare providers use mechanistic knowledge to individualise therapy, anticipate interactions, and monitor for treatment response and toxicity.

Clinical Indications

Flavedon 20mg Tablet (Trimetazidine 20mg) is clinically indicated for:

• Primary indication: stable angina pectoris (adjunct therapy when symptoms are not adequately controlled by first-line haemodynamic anti-anginal agents — beta-blockers, calcium channel blockers, nitrates) — EMA-restricted indication
• Specialist assessment required: Cardiovascular drug therapy must be initiated and monitored by a qualified cardiologist, physician, or specialist. Self-diagnosis and self-treatment of cardiac conditions is dangerous and may delay life-saving treatment.

Dosage and Administration

Immediate-release: 20mg 2–3 times daily with meals. Trimetazidine must be used as adjunctive therapy alongside standard first-line anti-anginal agents — not as monotherapy. Flavedon is the original Servier brand trimetazidine IR with the earliest clinical evidence base.

Never adjust the dose or stop cardiovascular medications without consulting your prescribing physician. Abrupt withdrawal of beta-blockers, anticoagulants, and anti-anginal drugs can cause dangerous rebound phenomena including angina exacerbation, myocardial infarction, and thromboembolic events.

Who Should Use Flavedon 20mg

Flavedon 20mg is indicated for adult patients in whom the relevant cardiovascular condition has been confirmed by clinical assessment and appropriate investigations (ECG, echocardiogram, cardiac biomarkers, blood pressure recording, coagulation studies as applicable) and in whom this specific pharmacological approach has been determined to be clinically appropriate after benefit-risk assessment.

Contraindications

Parkinson’s disease and Parkinsonian symptoms. Tremors, restless legs syndrome, and other movement disorders. Severe renal impairment (eGFR <30ml/min — reduce dose; avoid modified-release formulation in severe impairment). Hypersensitivity. The EMA has restricted trimetazidine to adjunctive therapy for stable angina when symptoms are not adequately controlled by first-line anti-anginal therapy.

Drug Interactions

No significant pharmacokinetic drug interactions reported. Additive anti-anginal benefit when combined with beta-blockers, calcium channel blockers, and nitrates (complementary mechanisms — metabolic vs haemodynamic) — this combination is the primary rationale for trimetazidine use.

Cardiovascular drugs have numerous clinically significant, potentially dangerous drug interactions. A comprehensive medication review by a cardiologist or clinical pharmacist is essential before initiating or changing any cardiac medication. Patients must inform all healthcare providers (including dentists, surgeons, and emergency physicians) of all their cardiovascular medications.

Adverse Effects

Common: GI effects (nausea, vomiting, abdominal pain — usually mild and dose-related). Dizziness. Important — Movement disorders: Trimetazidine is associated with drug-induced Parkinsonism, akathisia, tremor, and other extrapyramidal symptoms — particularly in elderly patients with prolonged use. The EMA has restricted trimetazidine use in patients with Parkinson’s disease, Parkinsonian symptoms, tremors, restless legs syndrome, or other movement disorders. Monitor for movement disorder symptoms and discontinue if these develop. Uncommon: Headache, rash, fatigue, cardiac palpitations.

Special Population Considerations

EMA Restricted Indication: The European Medicines Agency reviewed trimetazidine’s benefit-risk profile in 2012 and restricted its use to adjunctive therapy for stable angina in adults who remain symptomatic on standard first-line treatments (beta-blockers, calcium channel blockers, nitrates), and for symptomatic treatment of dizziness and tinnitus only when other treatments are inadequate. It should NOT be used as monotherapy for angina or as first-line treatment. Movement disorder monitoring: Monitor patients for any Parkinsonian features (tremor, rigidity, bradykinesia) during therapy — if symptoms develop, stop trimetazidine immediately. Regular neurological assessment is warranted in elderly patients on long-term therapy.

Storage and Handling

Store Flavedon 20mg at room temperature (15–25°C) in a dry location away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use beyond the printed expiry date. Nitroglycerin preparations require special storage in airtight glass containers away from heat — plastic and light degrade GTN. Enoxaparin: store at room temperature; do not freeze.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next scheduled dose. Never double-dose. Do not stop beta-blockers, anticoagulants, or anti-anginal medications abruptly without medical advice.

Q: How does trimetazidine relieve angina without affecting heart rate or blood pressure?
A: Trimetazidine’s anti-anginal mechanism is entirely metabolic — it works inside ischaemic heart cells rather than on the cardiovascular haemodynamic parameters targeted by beta-blockers, calcium channel blockers, and nitrates. By shifting myocardial energy production from inefficient fatty acid oxidation to more oxygen-efficient glucose oxidation, trimetazidine improves the heart cells’ ability to generate ATP under ischaemic conditions — reducing cell damage and symptoms without haemodynamic effects. This is why it is uniquely valuable as an add-on to haemodynamic agents.

Evidence Base and Cardiovascular Guidelines

The active ingredient in Flavedon 20mg has been evaluated in landmark randomised controlled trials and is supported by major international cardiovascular guidelines including those from the European Society of Cardiology (ESC), American College of Cardiology/American Heart Association (ACC/AHA), American Heart Association, National Institute for Health and Care Excellence (NICE), and relevant national cardiovascular specialist bodies. These guidelines represent evidence-based consensus on optimal pharmacological management of cardiovascular conditions and are regularly updated as new clinical evidence emerges.

Cardiovascular disease management has undergone transformative advances over the past three decades — from the landmark MERIT-HF, CAPRICORN, and EMPHASIS-HF trials establishing guideline-directed medical therapy for heart failure, to the COURAGE trial for stable angina, EINSTEIN for anticoagulation, and ADVANCE-HF for newer agents. Patients benefit most when their individual pharmacotherapy aligns with current evidence-based guidelines.

Patient Counselling Points

• Never stop abruptly: Beta-blockers, anti-anginal drugs, and anticoagulants must never be stopped suddenly without medical guidance — abrupt withdrawal can trigger angina rebound, myocardial infarction, arrhythmia, or thromboembolic events.
• Carry a medication list: All patients on cardiovascular drugs should carry a current medication list for any medical encounter — including surgical, dental, and emergency care. Drug interactions in cardiovascular patients can be life-threatening.
• Regular monitoring: Blood pressure, ECG, renal function, electrolytes (for diuretics), INR (for warfarin), platelet count (for heparins), and cardiac biomarkers as appropriate should be monitored at intervals determined by your cardiologist.
• Lifestyle integration: Pharmacotherapy delivers best results alongside appropriate lifestyle modification: Mediterranean diet, regular aerobic exercise, smoking cessation, moderate alcohol, sodium restriction for hypertension and heart failure.

Cardiovascular Disease Context and Clinical Management Principles

Cardiovascular disease (CVD) remains the leading cause of death globally, responsible for approximately 18 million deaths annually — representing 32% of all global mortality. Coronary artery disease, heart failure, hypertension, stroke, and peripheral arterial disease collectively impose an enormous burden of mortality, morbidity, and reduced quality of life worldwide. The last five decades have witnessed transformative advances in cardiovascular pharmacotherapy — from the introduction of beta-blockers and ACE inhibitors, through the development of statins and thrombolytics, to the current era of guideline-directed medical therapy with proven mortality-reducing agents for heart failure, and novel anticoagulants revolutionising stroke prevention in atrial fibrillation.

Effective cardiovascular disease management requires integration of pharmacological therapy with lifestyle modification (Mediterranean diet, regular aerobic exercise, smoking cessation, alcohol moderation, sodium restriction), risk factor control (blood pressure, lipid management, glycaemic control, weight management), and appropriate interventional or surgical procedures where indicated. Pharmacotherapy alone, without lifestyle integration and risk factor management, provides suboptimal benefit — drugs and lifestyle modification are synergistic, not alternative, approaches.

Hypertension: The Silent Cardiovascular Risk Factor

Hypertension affects approximately 1.28 billion adults worldwide, yet only 21% of hypertensive adults have their blood pressure adequately controlled. Uncontrolled hypertension is the leading modifiable risk factor for stroke, coronary artery disease, heart failure, renal failure, and peripheral arterial disease. The relationship between blood pressure and cardiovascular risk is continuous — even high-normal blood pressure (130–139/85–89 mmHg) carries increased cardiovascular risk compared to optimal levels.

Current international guidelines (ESC/ESH, ACC/AHA, NICE) recommend initial drug therapy for hypertension with one of three evidence-based drug classes: angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs); calcium channel blockers (CCBs); or thiazide/thiazide-like diuretics. Most patients with stage 2 hypertension (≥160/100 mmHg) require combination therapy from initial diagnosis. Fixed-dose combination tablets — such as those in this product range — improve adherence and simplify therapy for patients requiring multiple agents.

Angina Pectoris: Management Principles

Stable angina pectoris affects over 110 million people globally and represents myocardial ischaemia occurring predictably with exertion or emotional stress, relieved by rest or sublingual nitroglycerin within minutes. The management goal is threefold: symptom relief, prevention of disease progression and MI, and improvement of quality of life. First-line symptomatic therapy uses beta-blockers and/or calcium channel blockers as rate-limiting or vasodilatory agents; long-acting nitrates or nicorandil are added when first-line therapy is insufficient. For resistant symptoms, trimetazidine or ivabradine (when HR remains elevated) provide additional anti-anginal mechanisms. When pharmacological therapy fails to control symptoms adequately, coronary revascularisation (PCI or CABG) should be considered.

Quality Standards and Evidence Base

The active ingredients in products in this range have been evaluated in landmark randomised controlled trials that form the foundation of evidence-based cardiovascular medicine: MERIT-HF (metoprolol succinate in HFrEF), CAPRICORN and COPERNICUS (carvedilol in post-MI LV dysfunction and HFrEF), BEAUTIFUL (ivabradine in stable CAD), SIGNIFY (ivabradine in stable angina), EINSTEIN (enoxaparin in VTE), EXTRACT-TIMI 25 (enoxaparin in STEMI), and IONA (nicorandil in stable angina). Major cardiovascular guidelines from the ESC, ACC/AHA, and NICE incorporate these drugs into evidence-based treatment algorithms based on the totality of this evidence.

Products are manufactured in compliance with Good Manufacturing Practice (GMP) standards required by national and international pharmaceutical regulatory authorities, ensuring consistent quality, identity, strength, and purity. Patients should always obtain prescription cardiovascular medications from licensed pharmacies with valid prescriptions to ensure receipt of authentic, properly stored, quality-assured products.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed cardiology literature, and established clinical guidelines. It does not replace professional medical advice, diagnosis, or treatment from a qualified cardiologist, physician, or pharmacist. Cardiovascular drug therapy decisions must be individualised by a licensed healthcare provider with full knowledge of the patient’s cardiac status, comorbidities, and concurrent medications. Self-diagnosis and self-treatment of cardiovascular conditions can be dangerous and life-threatening. Always consult a qualified cardiologist or physician before starting, changing, or stopping any cardiovascular medication.